<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>The Precision Peptide Company Inc. News Releases</title>
		<link>https://feeds.newsfilecorp.com/company/8944</link>
		<description>Latest news from The Precision Peptide Company Inc., as distributed by TMX Newsfile.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Thu, 19 Nov 2026 07:22:50 -0500</lastBuildDate>
		<image>
			<url>https://images.newsfilecorp.com/logos/8944.jpg</url>
			<title>The Precision Peptide Company Inc. News Releases</title>
			<link>https://feeds.newsfilecorp.com/company/8944</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/company/8944"/>
		<item xml:lang="en">
			<title>The Precision Peptide Company Wins TikTok Shop Approval as Platform Tightens Peptide Rules, Putting U.S.-Made Peptide Products in Front of 53 Million American Buyers</title>
			<link>https://www.newsfilecorp.com/release/324790/The-Precision-Peptide-Company-Wins-TikTok-Shop-Approval-as-Platform-Tightens-Peptide-Rules-Putting-U.S.Made-Peptide-Products-in-Front-of-53-Million-American-Buyers</link>
			<description>Company gains access to more than 53 million U.S. buyers on a platform where beauty is the top category and products listing peptides as an ingredient command the highest average price of any top 10 beauty ingredient HighlightsApproved TikTok Shop storefront: The Company has been approved to operate its own TikTok Shop in the United States, giving it a direct sales channel to more than 53 million U.S. buyers.Approved under tighter rules: The approval follows TikTok's October 2026 move to...&lt;img src="https://api.newsfilecorp.com/newsinfo/324790/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 19 Nov 2026 07:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/324790</guid>
			<atom:subtitle>Company gains access to more than 53 million U.S. buyers on a platform where beauty is the top category and products listing peptides as an ingredient command the highest average price of any top 10 beauty ingredient</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Launches Free Shipping to All 50 States on Its U.S.-Made Over-the-Counter Range</title>
			<link>https://www.newsfilecorp.com/release/324399/The-Precision-Peptide-Company-Launches-Free-Shipping-to-All-50-States-on-Its-U.S.Made-OvertheCounter-Range</link>
			<description>A 50-state, U.S.-compounded peptide platform brought to market in 2026 HighlightsFree shipping to all 50 U.S. states on every product in the Company's over-the-counter range, effective immediatelySeven products, three formats: five capsules (BPC, KPV, Ageless, Chill and Blue), a copper-peptide topical serum (Hair) and the Recovery Patch: no needle, no mixing, no measuring, no refrigerationNo prescription required: the range is available to order directly from a dedicated storefront at...&lt;img src="https://api.newsfilecorp.com/newsinfo/324399/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 17 Nov 2026 07:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/324399</guid>
			<atom:subtitle>A 50-state, U.S.-compounded peptide platform brought to market in 2026</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Highlights a Landmark Year and Outlines 2027 Growth Priorities</title>
			<link>https://www.newsfilecorp.com/release/323397/The-Precision-Peptide-Company-Highlights-a-Landmark-Year-and-Outlines-2027-Growth-Priorities</link>
			<description>A 50-state, U.S.-compounded peptide platform brought to market in 2026, positioned ahead of the federal pathway for peptides HighlightsU.S. platform built and live: 503A compounding agreement, prescription and telehealth infrastructure, LegitScript Healthcare Merchant Certification and a consumer-facing website now serving all 50 U.S. statesThree formats, one brand: 16 clinician-prescribed therapies across seven therapy areas, plus a seven-product over-the-counter range of capsules, a topical...&lt;img src="https://api.newsfilecorp.com/newsinfo/323397/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Wed, 11 Nov 2026 07:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/323397</guid>
			<atom:subtitle>A 50-state, U.S.-compounded peptide platform brought to market in 2026, positioned ahead of the federal pathway for peptides</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Moves Early on New Federal Peptide Policy, Adding All Six Covered Peptides to Its Prescription Platform</title>
			<link>https://www.newsfilecorp.com/release/322628/The-Precision-Peptide-Company-Moves-Early-on-New-Federal-Peptide-Policy-Adding-All-Six-Covered-Peptides-to-Its-Prescription-Platform</link>
			<description>HighlightsAll six peptides covered by the new HHS policy being added: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 are being added to the Company's prescription platform, with availability to patients expected in November 2026Underway within a week of publication: the Company began adding all six peptides within a week of the policy's publication in the Federal Register on October 30, 2026Built to the policy's standards: each peptide will be prescribed as a single-ingredient compounded...&lt;img src="https://api.newsfilecorp.com/newsinfo/322628/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 05 Nov 2026 07:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322628</guid>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company's Needle-Free First Strategy Already in Place as HHS Draft Policy Recognizes Non-Injectable Routes for Leading Peptides</title>
			<link>https://www.newsfilecorp.com/release/322210/The-Precision-Peptide-Companys-NeedleFree-First-Strategy-Already-in-Place-as-HHS-Draft-Policy-Recognizes-NonInjectable-Routes-for-Leading-Peptides</link>
			<description>HighlightsFederal path for BPC-157: HHS has published a draft Enforcement Discretion Policy concerning a potential interim 503A compounding path for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500Needle-free routes recognized: oral and topical forms for BPC-157 and KPV, and intranasal use for Semax, now sit alongside injection in federal policyBuilt for the Company's model: the Policy runs through 503A compounding, a similar U.S. pathway behind the Company's 16-therapy...&lt;img src="https://api.newsfilecorp.com/newsinfo/322210/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 03 Nov 2026 07:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322210</guid>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas</title>
			<link>https://www.newsfilecorp.com/release/321522/The-Precision-Peptide-Company-Quadruples-U.S.-Telehealth-Formulary-to-16-Prescription-Therapies-Across-Seven-Therapy-Areas</link>
			<description>HighlightsPrescription formulary grows from 4 to 16 therapies in under 4 months since the Company's nationwide telehealth launchSeven therapy areas now covered: weight management, performance and growth hormone support, recovery, longevity and cellular health, immune support, cognitive health and sexual wellnessMulti-therapy stacked protocols introduced, allowing clinicians to combine therapies into a single personalized programThe Company's total portfolio now stands at 23 products across 3...&lt;img src="https://api.newsfilecorp.com/newsinfo/321522/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 29 Oct 2026 07:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/321522</guid>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Highlights 30 Years of Peptide Science Behind Its Product Platform</title>
			<link>https://www.newsfilecorp.com/release/321344/The-Precision-Peptide-Company-Highlights-30-Years-of-Peptide-Science-Behind-Its-Product-Platform</link>
			<description>HighlightsChief Scientific Officer Justin Kirkland brings three decades of hands-on peptide synthesis, analytical chemistry and formulation experience to the Company's product platformThe Company's approach centers on synthesis in the United States, an added purification step and independent third-party verificationScience-led development has already delivered the Company's needle-free BPC-157 Recovery Patch, independently tested at 95.5% purity and 2.02 mg of BPC-157 per patchVancouver, British...&lt;img src="https://api.newsfilecorp.com/newsinfo/321344/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Wed, 28 Oct 2026 07:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/321344</guid>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line</title>
			<link>https://www.newsfilecorp.com/release/320328/The-Precision-Peptide-Company-Locks-In-Exclusive-Manufacturing-Rights-Across-Its-NeedleFree-Line</link>
			<description>Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development HighlightsExclusive manufacturing rights secured for all four of the Company's patch formulations: BPC-157, Thymosin Alpha-1 (TA1), tirzepatide and GLP3Four patches, one U.S. manufacturer, one brand: each patch produced solely for The Precision Peptide CompanyThe Recovery Patch (BPC-157) is on sale now; 20,000 TA1 patches ordered, with...&lt;img src="https://api.newsfilecorp.com/newsinfo/320328/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 22 Oct 2026 07:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/320328</guid>
			<atom:subtitle>Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Begins Development of GLP3 Patch, Its Fourth Needle-Free Peptide</title>
			<link>https://www.newsfilecorp.com/release/319313/The-Precision-Peptide-Company-Begins-Development-of-GLP3-Patch-Its-Fourth-NeedleFree-Peptide</link>
			<description>Needle-free line grows to four U.S.-made patches in a peptide market projected to reach US$87.21 billion by 2035 1HighlightsGLP3 transdermal patch enters development in the United States, the fourth product in the Company's needle-free peptide patch lineGLP3 is the Company's second patch in the metabolic and weight-management category, following tirzepatideThe Recovery Patch (BPC-157) is on sale now; 20,000 Thymosin Alpha-1 patches ("TA1") ordered, with delivery expected in January 2027No...&lt;img src="https://api.newsfilecorp.com/newsinfo/319313/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 20 Oct 2026 07:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/319313</guid>
		</item>
		<item xml:lang="en">
			<title>The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing</title>
			<link>https://www.newsfilecorp.com/release/318635/The-Precision-Peptide-Company-Advances-NeedleFree-GLP1-Tirzepatide-Patch-into-Formal-U.S.-Testing</link>
			<description>Milestone advances the Company's transdermal peptide patch expanding the Company's growing portfolio across oral, topical and needle-free wellness formats HighlightsFormal U.S. testing now underway for the Company's needle-free tirzepatide GLP-1 transdermal patchTargets the US$66 billion global GLP-1 market, projected to reach US$185.3 billion by 2033²,³Existing tirzepatide products delivered by needle injection generated US$36.5 billion in 2025¹~11% of U.S. adults now use GLP-1 medications,...&lt;img src="https://api.newsfilecorp.com/newsinfo/318635/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 13 Oct 2026 07:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/318635</guid>
			<atom:subtitle>Milestone advances the Company's transdermal peptide patch expanding the Company's growing portfolio across oral, topical and needle-free wellness formats</atom:subtitle>
		</item>
	</channel>
</rss>
